Search clinical trials for: FCAS

Total 11 results

Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) (DFV890-FCAS)

Familial Cold Autoinflammatory Syndrome

United States, France, Germany
University of Manitoba
University of Washington; University of Toronto; Queen's University; Université...

Completed

EEG Guidance of Anesthesia (ENGAGES-CANADA) (ENGAGES)

Post-operative Delirium

Canada
University Hospital, Lille

Completed

Adult Outcomes of Children With CAPS (CAPS)

Cryopyrin Associated Periodic Syndrome

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Japan
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Germany, France, Belgium, Canada, Spain, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Muckle-Wells Syndrome | Neonatal Onset Multisystem Inflammatory Disease | Cryopyrin-associated Periodic Syndromes

Germany, France, Belgium, Canada, Spain, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

Cryopyrin Associated Periodic Syndrome

Canada
Handok Inc.

Terminated

HL2351 CAPS Phase II Study

Cryopyrin-Associated Periodic Syndromes (CAPS)

Korea, Republic of
Novartis

Completed

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Familial Cold Autoinflammatory Syndrome | Cryopyrin-Associated Periodic Syndromes | Neonatal Onset Multisystem Inflammatory Disease | Muckle Wells Syndrome

United States, Germany, Italy, Spain, United Kingdom, Turkey, France, Belgium, India
Novartis Pharmaceuticals

Completed

Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients (B-Confident)

Cryopyrin-associated Periodic Syndromes (CAPS) | Familial Cold Autoinflam Syn (FCAS) | Muckle-wells Syn (MWS) | Neonatal Onset Multisystem Inflam Disease (NOMID)

Switzerland, United States, Germany, Norway, Austria
Regeneron Pharmaceuticals

Completed

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

Genetic Diseases, Inborn | Familial Cold Autoinflammatory Syndrome (FCAS) | Familial Cold Urticaria | Muckle-Wells Syndrome (MWS)

United States

Search clinical trials for: FCAS

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations